Rio Nakamura

发表

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Ronald N. Jones, P. Rhomberg, H. Sader, 2016, The Journal of antimicrobial chemotherapy.

Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models

D. Nicolau, Kamilia Abdelraouf, Rio Nakamura, 2022, JAC-antimicrobial resistance.

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

T. Nishikawa, Akinobu Ito, Naoki Kohira, 2017, Antimicrobial Agents and Chemotherapy.

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

R. Echols, S. Rittenhouse, Rio Nakamura, 2017, Antimicrobial Agents and Chemotherapy.

Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities.

Rio Nakamura, S. Matsumoto, Toshiaki Aoki, 2022, ACS infectious diseases.

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Akinobu Ito, Naoki Kohira, J. West, 2015, Antimicrobial Agents and Chemotherapy.

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

H. Yoshizawa, Akinobu Ito, Rio Nakamura, 2016, Antimicrobial Agents and Chemotherapy.

Siderophore Cephalosporin Ceﬁderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

H. Yoshizawa, Akinobu Ito, Rio Nakamura, 2016 .

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.

H. Yoshizawa, H. Sugimoto, Rio Nakamura, 2018, European journal of medicinal chemistry.

Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.

S. Yonezawa, Rio Nakamura, M. Tsuji, 2016, European journal of medicinal chemistry.

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models

Rio Nakamura, M. Tsuji, Y. Yamano, 2019, Antimicrobial Agents and Chemotherapy.

248S-649266, a Novel Siderophore Cephalosporin: Efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion

J. Shimada, R. Echols, S. Rittenhouse, 2014 .

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

K. Tateda, Y. Ishii, K. Yamaguchi, 2016, Antimicrobial Agents and Chemotherapy.

Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.

Akinobu Ito, Rio Nakamura, M. Tsuji, 2014, The Japanese journal of antibiotics.

Evaluation of antibacterial activities of flomoxef against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.

Akinobu Ito, Rio Nakamura, M. Tsuji, 2013, The Japanese journal of antibiotics.

Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions

R. Echols, Rio Nakamura, M. Tsuji, 2017, Open Forum Infectious Diseases.

Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models.

D. Nicolau, Kamilia Abdelraouf, Rio Nakamura, 2021, The Journal of antimicrobial chemotherapy.

1626. Synergistic Effect of Cefiderocol with Other Antibiotics Against PER-Producing Acinetobacter baumannii Isolates from the Multinational SIDERO-WT Studies

R. Echols, Rio Nakamura, Y. Yamano, 2020 .

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia

Rio Nakamura, Y. Yamano, S. Matsumoto, 2021, Antimicrobial Agents and Chemotherapy.

1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp

D. Sahm, R. Nakai, Rio Nakamura, 2021, Open Forum Infectious Diseases.

1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp

D. Sahm, Rio Nakamura, Y. Yamano, 2021, Open Forum Infectious Diseases.

1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies

R. Echols, Rio Nakamura, Y. Yamano, 2020 .

[In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].

Akinobu Ito, Rio Nakamura, M. Tsuji, 2011, The Japanese journal of antibiotics.

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Akinobu Ito, Naoki Kohira, J. West, 2015, Antimicrobial Agents and Chemotherapy.

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

K. Tateda, Y. Ishii, K. Yamaguchi, 2016, Antimicrobial Agents and Chemotherapy.